These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 31324136)

  • 1. Liver Transplant From Increased-Risk Donors in the Era of Direct-Acting Antivirals for Hepatitis C.
    Shaikh OS; Rogal S; Malik A; Sharma V; Cacciarelli T
    Exp Clin Transplant; 2020 Oct; 18(5):605-611. PubMed ID: 31324136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre- Versus Posttransplant Treatment of Hepatitis C Virus With Direct-Acting Antivirals in Liver Transplant Recipients: More Issues to be Solved.
    Abdelqader A; Kabacam G; Woreta TA; Hamilton JP; Luu H; Al Khalloufi K; Saberi B; Philosophe B; Cameron AM; Gurakar A
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):1-5. PubMed ID: 28260422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver transplantation from anti-hepatitis C virus-positive donors: our experience.
    Álvaro E; Abradelo M; Fuertes A; Manrique A; Colina F; Alegre C; Calvo J; García M; García-Sesma A; Cambra F; Sanabria R; Moreno E; Jimenez C
    Transplant Proc; 2012; 44(6):1475-8. PubMed ID: 22841188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of Treating Hepatitis C Virus Infection Among Patients Awaiting Cadaveric Liver Transplant: A Single-Center Experience.
    Ofosu A; Durand CM; Saberi B; Alqahtani S; Ucbilek E; Belden M; Cameron AM; Gurakar A
    Exp Clin Transplant; 2015 Nov; 13 Suppl 3():7-10. PubMed ID: 26640901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver transplant recipients and prioritization of anti-HCV therapy: an Italian cohort analysis.
    Lanini S; Nanni Costa A; Grossi PA; Procaccio F; Ricci A; Capobianchi MR; Terrault NA; Ippolito G
    Liver Int; 2016 Mar; 36(3):410-7. PubMed ID: 26264452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.
    Lim KB; Sima HR; Fiel MI; Khaitova V; Doucette JT; Chernyiak M; Ahmad J; Bach N; Chang C; Grewal P; Kim-Schluger L; Liu L; Odin J; Perumalswami P; Florman SS; Schiano TD
    World J Gastroenterol; 2015 May; 21(20):6236-45. PubMed ID: 26034358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Organs From Hepatitis C Virus-Positive Donors for Uninfected Recipients: A Potential Cost-Effective Approach to Save Lives?
    Trotter PB; Summers DM; Ushiro-Lumb I; Robb M; Bradley JA; Powell J; Watson CJE; Neuberger J
    Transplantation; 2018 Apr; 102(4):664-672. PubMed ID: 29166338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrence of hepatitis C virus (genotype 4) infection after living-donor liver transplant in Egyptian patients.
    Yosry A; Abdel-Rahman M; Esmat G; El-Serafy M; Omar A; Doss W; Zayed N; Said M; Ismail T; Hosny A; Marawan E; El-Malt O; Kamel RR; Hatata Y; El-Taweel A; Ghali A; Sabri H; Kamel S; El-Gabaly H
    Exp Clin Transplant; 2009 Sep; 7(3):157-63. PubMed ID: 19715525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors.
    Kwong AJ; Wall A; Melcher M; Wang U; Ahmed A; Subramanian A; Kwo PY
    Am J Transplant; 2019 May; 19(5):1380-1387. PubMed ID: 30378723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in Utilization and Discard of HCV Antibody-Positive Deceased Donor Kidneys in the Era of Direct-Acting Antiviral Therapy.
    Bowring MG; Kucirka LM; Massie AB; Ishaque T; Bae S; Shaffer AA; Garonzik Wang J; Sulkowski M; Desai N; Segev DL; Durand CM
    Transplantation; 2018 Dec; 102(12):2088-2095. PubMed ID: 29912046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study.
    Feld JJ; Cypel M; Kumar D; Dahari H; Pinto Ribeiro RV; Marks N; Kamkar N; Bahinskaya I; Onofrio FQ; Zahoor MA; Cerrochi O; Tinckam K; Kim SJ; Schiff J; Reichman TW; McDonald M; Alba C; Waddell TK; Sapisochin G; Selzner M; Keshavjee S; Janssen HLA; Hansen BE; Singer LG; Humar A
    Lancet Gastroenterol Hepatol; 2020 Jul; 5(7):649-657. PubMed ID: 32389183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient.
    Campos-Varela I; Agudelo EZ; Sarkar M; Roberts JP; Terrault NA
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29125670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Sofosbuvir and Ribavirin for Eradicating Hepatitis C Virus in Renal Transplant Recipients in Pakistan: Where Resources Are Scarce.
    Hanif FM; Laeeq SM; Mandhwani RK; Luck NH; Aziz T; Mehdi SH
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):63-67. PubMed ID: 28260436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant.
    Yoshida EM; Kwo P; Agarwal K; Duvoux C; Durand F; Peck-Radosavljevic M; Lilly L; Willems B; Vargas H; Kumar P; Brown RS; Horsmans Y; De-Oertel S; Arterburn S; Dvory-Sobol H; Brainard DM; McHutchison JG; Terrault N; Rizzetto M; Müllhaupt B
    Ann Hepatol; 2017; 16(3):375-381. PubMed ID: 28425407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes.
    Axelrod DA; Schnitzler MA; Alhamad T; Gordon F; Bloom RD; Hess GP; Xiao H; Nazzal M; Segev DL; Dharnidharka VR; Naik AS; Lam NN; Ouseph R; Kasiske BL; Durand CM; Lentine KL
    Am J Transplant; 2018 Oct; 18(10):2473-2482. PubMed ID: 29701909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Hepatitis C Virus Antibody-Positive Donor Livers in Hepatitis C Nonviremic Liver Transplant Recipients.
    Luckett K; Kaiser TE; Bari K; Safdar K; Schoech MR; Apewokin S; Diwan TS; Cuffy MC; Anwar N; Shah SA
    J Am Coll Surg; 2019 Apr; 228(4):560-567. PubMed ID: 30586641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C transmission from seropositive, nonviremic donors to non-hepatitis C liver transplant recipients.
    Bari K; Luckett K; Kaiser T; Diwan T; Cuffy M; Schoech MR; Safdar K; Blackard JT; Apewokin S; Paterno F; Sherman KE; Zucker SD; Anwar N; Shah SA
    Hepatology; 2018 May; 67(5):1673-1682. PubMed ID: 29205441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.
    Shah AP; Cameron A; Singh P; Frank AM; Fenkel JM
    Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28060446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylaxis Among Hepatitis B Core Antibody-positive Deceased-donor Liver Transplant Recipients: Hepatitis B Immunoglobulin Plus Oral Antiviral Agents Versus Antiviral Agents Alone: A Single-center Experience.
    Malik MU; Ucbilek E; Trilianos P; Cameron AM; Gurakar A
    Exp Clin Transplant; 2017 Apr; 15(2):183-188. PubMed ID: 27212251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study.
    Verna EC; Saxena V; Burton JR; O'Leary JG; Dodge JL; Stravitz RT; Levitsky J; Trotter JF; Everson GT; Brown RS; Terrault NA;
    Transplantation; 2015 Aug; 99(8):1644-51. PubMed ID: 25715116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.